drug · antibody

BLINCYTO

updated 3mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.

targets

B-lymphocyte antigen CD19T cell surface glycoprotein CD3

all catalysts(0)

nothing on the calendar yet

Trials studying BLINCYTO

phase2A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemianot yet recruitingn=26
phase2A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseasesrecruitingn=220
phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340
phase2Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemiacompletedn=19
phase2Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemiarecruitingn=40
phase1Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)completedn=6
phase1Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemiaactive not recruitingn=20
phase3A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemiarecruitingn=6,430

more trials →

News(0)

no news has mentioned this drug yet

brand

BLINCYTO

trade names

Blincyto

generic

BLINATUMOMAB

MOA

12.1 Mechanism of Action Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. Blinatumomab mediates the formation of a synapse between the T-cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, which result in redirected lysis of CD19+ cells.

indication

1 INDICATIONS AND USAGE BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 ) 1.1 MRD-positive B-cell Precursor ALL BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older. 1.2 Relapsed or Refractory B-cell Precursor ALL BLINCYTO is indicated for the treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older. 1.3 B-cell Precursor ALL in the Consolidation Phase BLINCYTO is indicated for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older.

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

BLINCYTO

updated 3mo ago

by $AMGN AMGEN INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.

targets

B-lymphocyte antigen CD19T cell surface glycoprotein CD3

all catalysts(0)

nothing on the calendar yet

Trials studying BLINCYTO

phase2A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemianot yet recruitingn=26
phase2A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseasesrecruitingn=220
phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340
phase2Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemiacompletedn=19
phase2Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemiarecruitingn=40
phase1Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)completedn=6
phase1Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemiaactive not recruitingn=20
phase3A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemiarecruitingn=6,430

more trials →

News(0)

no news has mentioned this drug yet

brand

BLINCYTO

trade names

Blincyto

generic

BLINATUMOMAB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

BLINCYTO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying BLINCYTO

News(0)

Report a data issue

comments(0)

BLINCYTO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying BLINCYTO

News(0)

Report a data issue

comments(0)